Strides Pharma Science Ltd Share Price
(STAR)
₹641.2▲1.22%
as on 04:01PM, 19 Mar 2025
🔔 Demerger and Acquisition Alert
Strides Pharma to demerge from Arco Labs and acquire 100% stake in Amexel Pte. Ltd. for US $10.
Strides Pharma Science Ltd Performance
Day's Low
Day's High
₹627Day's Price Range₹65252 Week's Low
52 Week's High
₹53052-Week Price Range₹1,675
| Returns % | |
| 1 Month Return | + 0.8 % |
| 3 Month Return | -9.4 % |
| 1 Year Return | -17.61 % |
| Market Stats | |
| Previous Close | ₹633.50 |
| Open | ₹634.90 |
| Volume | 4.32L |
| Upper Circuit | ₹760.20 |
| Lower Circuit | ₹506.80 |
| Market Cap | ₹5,838.51Cr |
Strides Pharma Science Ltd Fundamentals
P/E Ratio
36.84
PEG Ratio
1.67
Market Cap
₹5,838.51 Cr
P/B Ratio
2.02
EPS
-4.49599698514042
Dividend Yield
0.32
Sector
Pharmaceuticals
ROE
1.87
Mutual Fund Holdings of Strides Pharma Science Ltd
Strides Pharma Science Ltd Analyst Rating
based on 3 analysts
66.67%
Buy
0.00%
Hold
33.33%
Sell
Based on 3 analysts offering long term price targets for Strides Pharma Science Ltd. An average target of ₹1373
Source: S&P Global Market Intelligence
Strides Pharma Science Ltd Share analysis
Strides Pharma Science Ltd price forecast by 3 analysts
Upside of116.73%
High
₹1874
Target
₹1373.00
Low
₹1070
Strides Pharma Science Ltd target price ₹1373, a slight upside of 116.73% compared to current price of ₹641.2. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Strides Pharma Science Ltd revenue growth forecast
Expected growth rate Q1, FY2027:42.39%
Forecast
Actual
Including amortisation and stock based compensations
Strides Pharma Science Ltd EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
What's happening today
Today's Timeline - Invalid Date
12:04 PM
-Strides Pharma announces in-principle approval for demerger from Arco Labs, creating a new wholly-owned subsidiary focused on Life Sciences.
Key events for Strides Pharma Science Ltd
Strides Pharma Announces Demerger from Arco Labs - 19 Mar, 2025
Strides Pharma Science Limited has received in-principle approval for a demerger from Arco Labs, establishing a new subsidiary focused on Life Sciences. Additionally, the company has dissolved its non-operating subsidiary, Generic Partners UK.Strides Pharma Gains from Singapore Acquisition - 17 Mar, 2025
Strides Pharma's share price rose by 3% following its Singapore subsidiary's acquisition of a 100% stake in Amexel Pte. The acquisition aims to enhance collaborations and business engagements in the pharmaceutical sector across India, China, and Southeast Asia.Strides Pharma Acquires Amexel for Strategic Growth - 15 Mar, 2025
Strides Pharma Science announces the acquisition of Singapore-based Amexel for USD 10. This acquisition aims to enhance collaborations and procurement in the pharmaceutical sector across India and Southeast Asia.OneSource Seeks Clarification on Regulatory Exemption - 06 Mar, 2025
OneSource is in a scheme of arrangement with Strides Pharma Science and Steriscience Specialties. It seeks clarification on availing an exemption under Regulation 172(1)(b) based on Strides' listing history.
Insights on Strides Pharma Science Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPromoter Holding Up
Promoters have increased holdings from 25.84% to 26.82% in Dec 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 10.80% to 10.86% in Dec 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 25.83% to 27.77% in Dec 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 18.18 Cr → 87.95 Cr (in ₹), with an average increase of 31.6% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 67.5% return, outperforming this stock by 85.1%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 126.9% return, outperforming this stock by 47.0%
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 1.19K Cr → 1.16K Cr (in ₹), with an average decrease of 2.9% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 30.08% to 28.48% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 6 months, STAR stock has moved down by -52.3%
Strides Pharma Science Ltd Financials
Strides Pharma Science Ltd Index Inclusions
Strides Pharma Science Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.82% | 3.81 | |
| Foreign Institutions | 28.48% | ||
| Mutual Funds | 10.86% | 0.57 | |
| Retail Investors | 27.77% | 7.48 | |
| Others | 6.07% |
Strides Pharma Science Ltd Key Indicators
Strides Pharma Science Ltd Valuation
Strides Pharma Science Ltd in the last 5 years
Lowest (-409.06x)
July 5, 2021
Today (36.84x)
March 18, 2025
Industry (51.23x)
March 18, 2025
Highest (6306.63x)
September 27, 2024
Strides Pharma Science Ltd Earnings and Dividends
Strides Pharma Science Ltd Earnings Results
Strides Pharma Science Ltd’s net profit jumped 77.07% since last year same period to ₹87.95Cr in the Q3 2024-2025. On a quarterly growth basis, Strides Pharma Science Ltd has generated 22.42% jump in its net profits since last 3-months.
Read More about Earnings ResultsStrides Pharma Science Ltd Dividends May,2024
In the quarter ending March 2024, Strides Pharma Science Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.62%.
Read More about Dividends
Strides Pharma Science Ltd Technicals Summary
Bearish
Neutral
Bullish
Strides Pharma Science Ltd is currently in a Neutral trading position according to technical analysis indicators.
Strides Pharma Science Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹5,838.51 Cr | 25.77% | 0.66 | -₹95 Cr | ₹4,051 Cr | |
| NA | ₹47.23 Cr | 12.95% | 0.68 | NA | NA | |
| NA | ₹115.89 Cr | 84.64% | 0.50 | NA | NA | |
| NA | ₹1,439.94 Cr | 549.29% | 0.52 | NA | NA | |
| NA | ₹21.77 Cr | 25.86% | 0.52 | NA | NA |
About Strides Pharma Science Ltd
Revenue: ₹1,153.67Cr as on December 2024 (Q4 24)
Net Profit: ₹90.04Cr as on December 2024 (Q4 24)
Listing date: 02 Feb, 2000
Chairperson Name: Arun Kumar
| Organisation | Strides Pharma Science Ltd |
| Headquarters | Bangaluru |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Strides Pharma Science Ltd
What is Strides Pharma Science Ltd price today?
Strides Pharma Science Ltd share price today stands at ₹641.2, Open: ₹634.9, Previous Close: ₹633.5, High: ₹652, Low: ₹627, 52 Week High: ₹1675, 52 Week Low: ₹530.
How to Buy Strides Pharma Science Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Strides Pharma Science Ltd shares
What are today's traded volumes of Strides Pharma Science Ltd?
Today's traded volume of Strides Pharma Science Ltd(STAR) is 4.32L.
What is today's market capitalisation of Strides Pharma Science Ltd?
Today's market capitalisation of Strides Pharma Science Ltd(STAR) is ₹5838.51Cr.
What is the 52 Week High and Low Range of Strides Pharma Science Ltd?
How much percentage Strides Pharma Science Ltd is down from its 52 Week High?
Strides Pharma Science Ltd (STAR) share price is ₹641.2. It is down -61.72% from its 52 Week High price of ₹1675
How much percentage Strides Pharma Science Ltd is up from its 52 Week low?
Strides Pharma Science Ltd (STAR) share price is ₹641.2. It is up 20.98% from its 52 Week Low price of ₹530